- Sativex for the management of multiple sclerosis symptoms
- THC & CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
- Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity
- CBD provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
- Oromucosal delta9-THC/CBD for neuropathic pain associated with multiple sclerosis
- Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis
- Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis
- A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
- Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
- Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
- Evaluating Sativex in Neuropathic Pain Management
- CBD counteracted the development of experimental MS
- CBD/THC Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice